Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981602541> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2981602541 endingPage "S956" @default.
- W2981602541 startingPage "S955" @default.
- W2981602541 abstract "Adjuvant chemotherapy using cisplatin is recommended for patients with lung cancer p-stage IB-IIIA, who were received surgical resection completely. In order to improve the prognosis of the patients with lung cancers, we need to find a new predictive factor for anti-cancer agents and establish a new regimen for the adjuvant chemotherapy. We have previously reported that anti-aging gene Klotho expression was a prognostic factor for small cell lung cancer and LCNEC so far. Therefore, in this study, we investigate the association between the expression of Klotho and the sensitivity against anti-cancer agents, and we examined the anti-tumor tumor effect of Klotho expression. We established a cell line, A549/Klotho, which stably overexpress Klotho, and then examined the association between the expression of Klotho and Epithelial-Mesenchymal Transition related proteins such as N-cadherin, E-cadherin, Snail, Vimentin, etc. Next, we performed the sensitivity test for various anticancer agents including pemetrexed, CDDP, paclitaxel, gefitinib, etc, using A549 cells and A549/Klotho cells. Moreover, we evaluated the role of Klotho expression against anti-tumor effect. By western blot analysis, the expression of N-cadherin was completely inhibited in A549/Klotho cells, but in A549 cells. This result suggested that Klotho expression may regulate the expression of N-cadherin and Klotho can play an important role in cancer metastasis/invasion by regulating EMT. Moreover, we clarified that miR145 was related to the inhibition of N-cadherin in analysis of A549/Klotho cells but not miR218, miR67. A549/Klotho cells were more sensitive seven times against pemetrexed compared to A549 cells (IC50; 0.1 micro M) by MTT assay. There is no difference of sensitivity between A549/Klotho cells and A549 cells against molecular target drugs such as gefitinib, other kinds of TKI. From these results, we conclude that overexpression of Klotho may regulate the sensitivity against pemetrexed through the inhibition of expression of mir145 and N-cadherin. In the future, we may establish a new strategy of chemotherapy for patients with advanced lung cancer based on the expression of anti-aging gene Klotho." @default.
- W2981602541 created "2019-11-01" @default.
- W2981602541 creator A5021017777 @default.
- W2981602541 creator A5037099107 @default.
- W2981602541 date "2019-10-01" @default.
- W2981602541 modified "2023-09-30" @default.
- W2981602541 title "EP1.03-10 Expression of Anti-Aging Gene, Klotho Is a Surrogate Marker of Pemetrexed for Lung Cancer Treatment" @default.
- W2981602541 doi "https://doi.org/10.1016/j.jtho.2019.08.2087" @default.
- W2981602541 hasPublicationYear "2019" @default.
- W2981602541 type Work @default.
- W2981602541 sameAs 2981602541 @default.
- W2981602541 citedByCount "0" @default.
- W2981602541 crossrefType "journal-article" @default.
- W2981602541 hasAuthorship W2981602541A5021017777 @default.
- W2981602541 hasAuthorship W2981602541A5037099107 @default.
- W2981602541 hasBestOaLocation W29816025411 @default.
- W2981602541 hasConcept C121608353 @default.
- W2981602541 hasConcept C126322002 @default.
- W2981602541 hasConcept C143998085 @default.
- W2981602541 hasConcept C147447768 @default.
- W2981602541 hasConcept C204232928 @default.
- W2981602541 hasConcept C2776256026 @default.
- W2981602541 hasConcept C2776694085 @default.
- W2981602541 hasConcept C2777240266 @default.
- W2981602541 hasConcept C2778239845 @default.
- W2981602541 hasConcept C2779013556 @default.
- W2981602541 hasConcept C2780091579 @default.
- W2981602541 hasConcept C502942594 @default.
- W2981602541 hasConcept C71924100 @default.
- W2981602541 hasConcept C76419328 @default.
- W2981602541 hasConcept C81729549 @default.
- W2981602541 hasConcept C9832595 @default.
- W2981602541 hasConceptScore W2981602541C121608353 @default.
- W2981602541 hasConceptScore W2981602541C126322002 @default.
- W2981602541 hasConceptScore W2981602541C143998085 @default.
- W2981602541 hasConceptScore W2981602541C147447768 @default.
- W2981602541 hasConceptScore W2981602541C204232928 @default.
- W2981602541 hasConceptScore W2981602541C2776256026 @default.
- W2981602541 hasConceptScore W2981602541C2776694085 @default.
- W2981602541 hasConceptScore W2981602541C2777240266 @default.
- W2981602541 hasConceptScore W2981602541C2778239845 @default.
- W2981602541 hasConceptScore W2981602541C2779013556 @default.
- W2981602541 hasConceptScore W2981602541C2780091579 @default.
- W2981602541 hasConceptScore W2981602541C502942594 @default.
- W2981602541 hasConceptScore W2981602541C71924100 @default.
- W2981602541 hasConceptScore W2981602541C76419328 @default.
- W2981602541 hasConceptScore W2981602541C81729549 @default.
- W2981602541 hasConceptScore W2981602541C9832595 @default.
- W2981602541 hasIssue "10" @default.
- W2981602541 hasLocation W29816025411 @default.
- W2981602541 hasOpenAccess W2981602541 @default.
- W2981602541 hasPrimaryLocation W29816025411 @default.
- W2981602541 hasRelatedWork W2008753571 @default.
- W2981602541 hasRelatedWork W2358450743 @default.
- W2981602541 hasRelatedWork W2381460883 @default.
- W2981602541 hasRelatedWork W2406858132 @default.
- W2981602541 hasRelatedWork W2480785262 @default.
- W2981602541 hasRelatedWork W2603922820 @default.
- W2981602541 hasRelatedWork W2757419532 @default.
- W2981602541 hasRelatedWork W3032772405 @default.
- W2981602541 hasRelatedWork W3121682002 @default.
- W2981602541 hasRelatedWork W4281649588 @default.
- W2981602541 hasVolume "14" @default.
- W2981602541 isParatext "false" @default.
- W2981602541 isRetracted "false" @default.
- W2981602541 magId "2981602541" @default.
- W2981602541 workType "article" @default.